| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/20/2005 | US20050014698 Antioxidat food; polypeptide containing methionine, cysteine |
| 01/20/2005 | US20050014695 Uses of a chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014686 Somatostatin analogues |
| 01/20/2005 | US20050014404 Apparatus for a quick release safety connector assembly |
| 01/20/2005 | US20050014188 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 01/20/2005 | US20050014187 Novel polypeptide hormone phosphatonin |
| 01/20/2005 | US20050014158 Using presence of polymorphic sequences in gene associated with phospholipase to diagnose, prognose and treat non-insulin dependent diabetes mellitus and obesity |
| 01/20/2005 | US20050014149 Assay for inhibitors of translocases |
| 01/20/2005 | US20050013877 Strontium compound for treatment of sub-dermal soft tissue pain |
| 01/20/2005 | US20050013875 Immunopotentiators in thermotherapy for cancer |
| 01/20/2005 | US20050013868 Preparation of submicron sized nanoparticles via dispersion lyophilization |
| 01/20/2005 | US20050013814 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 01/20/2005 | US20050013805 Device and method for delivery of rapidly separating body of fluid, forming bone reconstruction medium |
| 01/20/2005 | US20050013794 Mixture of addition polymer and polyguanidine microbiocides |
| 01/20/2005 | US20050013791 Cytokine-inducing material and cytokine-inducing instrument |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531407A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 01/20/2005 | CA2530967A1 Inhibition of stress-induced ligand-dependent egfr activation |
| 01/20/2005 | CA2530314A1 Appl proteins as rab5 effectors |
| 01/20/2005 | CA2529304A1 Non-invasive intravascular thrombolysis using modified ultrasound techniques |
| 01/19/2005 | EP1498479A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1498140A2 Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| 01/19/2005 | EP1498139A1 Novel thrombomodulin expression promoters |
| 01/19/2005 | EP1498136A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1498129A1 Use of adenoviruses mutated in the va genes for cancer treatment |
| 01/19/2005 | EP1498128A1 Medicinal compositions containing phtocrosslinkable chitosan derivative |
| 01/19/2005 | EP1498127A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1498101A1 Composition for cell proliferation |
| 01/19/2005 | EP1497662A1 Uses of the carbamoyl phosphate synthesis 1 (cps 1) and the fragments thereof for the diagnosis of inflammatory diseases and sepsis |
| 01/19/2005 | EP1497659A2 An ephrin-b receptor protein involved in carcinoma |
| 01/19/2005 | EP1497658A2 Protein involved in cancer |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497462A2 Genomic screen for epigenetically silenced genes associated with cancer |
| 01/19/2005 | EP1497427A2 Helicokinin-receptor from insects |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497424A1 Oligonucleotide compositions and their use for the modulation of immune responses |
| 01/19/2005 | EP1497420A2 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| 01/19/2005 | EP1497419A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof |
| 01/19/2005 | EP1497327A2 Method for the identification of inhibitors of the binding of are-containing mrna and an hur protein |
| 01/19/2005 | EP1497319A2 Cell adhesion and extracellular matrix proteins |
| 01/19/2005 | EP1497315A2 Nucleic acid-associated proteins |
| 01/19/2005 | EP1497289A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 01/19/2005 | EP1497288A1 Novel ester hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, methods for the production thereof, and use thereof as a medicament |
| 01/19/2005 | EP1497287A1 Quinolinone derivatives |
| 01/19/2005 | EP1497280A1 Indol-2-ones as selective inhibitors of cyclooxygenase-2 |
| 01/19/2005 | EP1497271A1 Indane acetic acid derivatives and their use as pharmaceutical agents |
| 01/19/2005 | EP1497268A2 Nitric oxide donors, compositions and methods of use |
| 01/19/2005 | EP1496981A2 Method of treating cancer |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496933A2 Use of interleukin-19 to treat ovarian cancer |
| 01/19/2005 | EP1496932A2 Anti-hiv composition, production method thereof and medicament |
| 01/19/2005 | EP1496929A1 Use of c5a receptor antagonist in the treatment of fibrosis |
| 01/19/2005 | EP1496925A2 Use of interleukin-24 to treat ovarian cancer |
| 01/19/2005 | EP1496918A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 01/19/2005 | EP1496917A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 01/19/2005 | EP1496912A1 Combination of brimonidine and timolol for topical ophthalmic use |
| 01/19/2005 | EP1496908A1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
| 01/19/2005 | EP1496907A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496901A2 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 01/19/2005 | EP1496900A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 01/19/2005 | EP1496898A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496896A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496893A2 Neuroprotectant methods, compositions, and screening methods thereof |
| 01/19/2005 | EP1496891A2 Methods for modulating phototoxicity |
| 01/19/2005 | EP1496881A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 01/19/2005 | EP1496880A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| 01/19/2005 | EP1496879A1 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
| 01/19/2005 | EP1496878A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| 01/19/2005 | EP1496877A2 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states |
| 01/19/2005 | EP1496863A2 Preparation and use of a stable formulation of allosteric effector compounds |
| 01/19/2005 | EP1496861A2 Method of inhibiting restenosis |
| 01/19/2005 | EP1496836A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| 01/19/2005 | EP1496835A2 Compositions and methods for systemic inhibition of cartilage degradation |
| 01/19/2005 | EP1496824A2 Tissue composites and uses thereof |
| 01/19/2005 | EP1496742A1 Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins |
| 01/19/2005 | EP1355633B1 NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate |
| 01/19/2005 | EP1265615B1 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 01/19/2005 | EP1200080A4 Assay for d-serine transport antagonist and use for treating psychosis |
| 01/19/2005 | EP1124562B1 Combination therapy to treat hepatitis b virus |
| 01/19/2005 | EP1100589B1 Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| 01/19/2005 | EP0941116B1 Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device |
| 01/19/2005 | EP0933995B8 Method of treating endothelial injury |
| 01/19/2005 | EP0784429B1 Therapeutic combinations of venous dilators and arterial dilators |
| 01/19/2005 | EP0545946B1 Growth-promoting agent |
| 01/19/2005 | CN1568374A Method for identifying compounds modulating reverse cholesterol transport |
| 01/19/2005 | CN1568373A RNA interference mediating small rna molecules |
| 01/19/2005 | CN1568365A Composition comprising a lactobacillus pentosus strain and uses thereof |
| 01/19/2005 | CN1568313A Piperidine compounds as muscarinic antagonists |
| 01/19/2005 | CN1568307A Aminopyridyl-substituted phenyl acetamides as protease inhibitors |
| 01/19/2005 | CN1568198A Use of cd23 antagonists for the treatment of neoplastic disorders |
| 01/19/2005 | CN1568196A Nutrient therapy for immuno-compromised patients |
| 01/19/2005 | CN1568195A Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| 01/19/2005 | CN1568194A Modulation of smooth muscle cell proliferation |
| 01/19/2005 | CN1568193A Use of il-18 inhibitors in hypersensitivity disorders |
| 01/19/2005 | CN1568190A Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |